As CVS sharpens its focus on customer health, the nation's second-largest drugstore chain will tweak its corporate name and stop the sale of tobacco nearly a month sooner than planned. CVS Caremark said it will now be known as CVS Health, effective immediately. The signs on its roughly 7,700 drugstores won't change, so the tweak may not register with shoppers.
PPD has acquired RCT Logic’s exclusive license from Massachusetts General Hospital for the portfolio of patents related to its sequential parallel comparison design (SPCD). SPCD is an alternative method for conducting well-controlled clinical trials that substantially decreases the impact on trial outcomes of any placebo effect.
Zoetis has received conditional approval from federal regulators for a vaccine that helps fight a virus that has killed millions of piglets since it started showing up in the United States last year. The company said that its vaccine for the porcine epidemic diarrhea virus should be available to veterinarians and pig farmers this month.
Ajinomoto Althea announced today that it has officially received its European GMP certificate issued by the MHRA. The MHRA conducted an on-site inspection on June 19, 2014 that yielded no critical or major observations. This certification provides clearance to Althea to test commercial drug product for the European market.
The CDC issued a dire warning about Ebola, and CNN's Sanjay Gupta explains the challenge of containing the outbreak.
AstraZeneca has entered into a research collaboration with Redx Pharma Limited to discover and develop new molecules targeting a genetic driver of tumor growth and survival. The research will complement AstraZeneca’s strategic approach focused on genetic drivers of cancer and mechanisms of resistance to established and novel cancer therapies.
A British nurse infected with Ebola was discharged Wednesday from a London hospital after making a full recovery, the hospital said. William Pooley, 29, contracted the deadly disease while treating Ebola patients in Sierra Leone.
Removing both breasts to treat cancer affecting only one side doesn't boost survival chances for most women, compared with surgery that removes just the tumor, a large study suggests. The results raise concerns about riskier, potentially unnecessary operations that increasing numbers of women are choosing.
Teva Pharmaceutical announced that a positive judgment has been given by the UK High Court in support of Teva's case against AstraZeneca relating to the validity of EP 1,085,877 covering the SMART ( S ingle inhaler M aintenance A nd R eliever T herapy) indication for AstraZeneca's fixed dose formoterol/budesonide combination product, Symbicort®.
Under the terms of the agreement, Infinity will receive an upfront payment of $275 million and is eligible to receive up to $530 million in additional payments for the achievement of development, regulatory and commercial milestones, including up to $405 million for the achievement of milestones through the first commercial sale of duvelisib.
Eisai today announced it has entered into an agreement with Concordia Pharmaceuticals Inc., a subsidiary of Concordia Healthcare Corp., to purchase Eisai's U.S. and Puerto Rican commercialization and distribution rights to Zonegran.
Introducing an economical and simple-to-use stainless steel tablet hardness tester that accurately calculates the hardness and thickness of solid dosage forms.
The line of Gastec pumps and detector tubes precisely measure gases and vapors in over 600 applications, making it a suitable tool for gas detection and measurement as well as detecting leaks and fugitive emissions.
Introducing the ECX-001 Case Packer, a jointly-developed semi-automatic case packer with unit-level serialization capabilities that has been outfitted with best in class software, cameras, and printers to meet the more stringent track & trace requirements mandated by the Drug Quality and Security Act.
Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing ResourcesSeptember 2, 2014 2:39 pm | News | Comments
Particle Sciences, a CDMO for drug eluting devices, has added to its investment in development and manufacturing capabilities with the addition of a new 18mm extruder. The company now has over 6000ft2 of operating cleanroom and cGMP warehouse space including ISO5 (sterile) and two dedicated highly potent suites.